World Health Organization site
Skip Navigation Links

Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: ChiCTR
Last refreshed on: 16 March 2020
Main ID:  ChiCTR2000029816
Date of registration: 2020-02-14
Prospective Registration: Yes
Primary sponsor: Guangzhou reborn health management consultation co., LTD
Public title: Cancelled by the investigator Clinical Study for Cord Blood Mesenchymal Stem Cells in the Treatment of Acute Novel Coronavirus Pneumonia (COVID-19)
Scientific title: Clinical Study of Cord Blood Mesenchymal Stem Cells in the Treatment of Acute Novel Coronavirus Pneumonia (COVID-19)
Date of first enrolment: 2020-02-20
Target sample size: Experimental group:30;Control group :30;
Recruitment status: Pending
URL:  http://www.chictr.org.cn/showproj.aspx?proj=49389
Study type:  Interventional study
Study design:  Parallel  
Phase:  0
Countries of recruitment
Contacts
Name: Chao Xu   
Address:  85 Kefeng Road, Hi-Tech Development District, Guangzhou, Guangdong, China
Telephone: +86 15018720816
Email: 164972769@qq.com
Affiliation:  Guangzhou reborn health management consultation co., LTD
Name: Chao Xu   
Address:  85 Kefeng Road, Hi-Tech Development District, Guangzhou, Guangdong, China
Telephone: +86 15018720816
Email: 164972769@qq.com
Affiliation:  Guangzhou reborn health management consultation co., LTD
Key inclusion & exclusion criteria
Inclusion criteria: 1. Patients with confirmed new coronavirus-infected pneumonia;
2. Voluntarily sign written informed consent.

Exclusion criteria: 1. Extremely ill patients with shock, acute respiratory distress syndrome, and multiple organ failure;
2. Pregnant or lactating women;
3. In the opinion of the investigator, previous or present illnesses may affect patients' participation in the trial or influence the outcome of the study, including: malignant disease, autoimmune disease, liver and kidney disease, blood disease, neurological disease, and endocrine Disease; currently suffering from diseases that seriously affect the immune system, such as: human immunodeficiency virus (HIV) infection, or the blood system, or splenectomy, organ transplantation, etc.;
4. The investigator believes that the patient has other conditions that are not suitable for enrollment


Age minimum: 18
Age maximum:
Gender: Both
Health Condition(s) or Problem(s) studied
Novel Coronavirus Pneumonia (COVID-19)
Intervention(s)
Experimental group:Conventional treatment followed by Intravenous infusion of Cord Blood Mesenchymal Stem Cells preparations ;Control group :Conventional treatment ;
Primary Outcome(s)
Time to disease recovery;
Secondary Outcome(s)
Time and rate of coronavirus become negative;Clearance rate and time of main symptoms (fever, fatigue, cough);Exacerbation (transfer to RICU) time;Routine blood test;Biochemical Indicators;Immune indices;
Secondary ID(s)
Source(s) of Monetary Support
self-financing
Secondary Sponsor(s)
Ethics review
Status: Not approved
Approval date: 26/08/2013
Contact:
Results
Results available:
Date Posted:
Date Completed:
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history